ARTICLE | Clinical News
Sound begins Phase IIb of SPI-1005 for Meniere's disease
October 6, 2017 4:54 PM UTC
Sound Pharmaceuticals Inc. (Seattle, Wash.) began the double-blind, placebo-controlled Phase IIb SPI-1005-251 trial of ebselen (SPI-1005) for 28 days in 120 patients with Meniere's disease. The trial will evaluate safety and include assessments of hearing loss, tinnitus and vertigo...
BCIQ Company Profiles
BCIQ Target Profiles